{"denoms":[{"counts":[{"groupId":"BG000","value":"790"},{"groupId":"BG001","value":"789"},{"groupId":"BG002","value":"1579"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\\^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\\^2 orally twice a day (BID) on Days 1 to 14 Q3W (CAPOX regimen).\n\nParticipants who completed up to 35 administrations of pembrolizumab (approximately 2 years) or achieved a complete response (CR) but experienced progression of disease (PD), could have initiated a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).","id":"BG000","title":"Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)"},{"description":"Participants received placebo on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\\^2 IV on Day 1 Q3W and 5FU 800 mg/m\\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\\^2 orally BID on Days 1 to 14 Q3W (CAPOX regimen).","id":"BG001","title":"Placebo + Chemotherapy (FP or CAPOX Regimen)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.9","value":"59.3"},{"groupId":"BG001","spread":"11.8","value":"60.0"},{"groupId":"BG002","spread":"11.8","value":"59.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"263"},{"groupId":"BG001","value":"245"},{"groupId":"BG002","value":"508"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"527"},{"groupId":"BG001","value":"544"},{"groupId":"BG002","value":"1071"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"332"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"615"},{"groupId":"BG002","value":"1205"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"42"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"67"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"270"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"539"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"21"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"426"},{"groupId":"BG001","value":"435"},{"groupId":"BG002","value":"861"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"73"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"618"},{"groupId":"BG001","value":"617"},{"groupId":"BG002","value":"1235"}]}],"title":"CPS ≥1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"344"}]}],"title":"CPS <1"}],"description":"PD-L1 positivity at baseline was determined by immunohistochemistry (IHC) using both tumor and blood cells. Participants were stratified (CPS \\<1 versus CPS ≥1) and some efficacy outcome measures were presented using a CPS cutoff of CPS ≥1 at baseline. Participants with a CPS \\<1 were classified as PD-L1 negative, participants with a CPS≥1 were classified as PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) <1 and CPS ≥1 Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"280"},{"groupId":"BG001","value":"273"},{"groupId":"BG002","value":"553"}]}],"title":"CPS ≥10"},{"categories":[{"measurements":[{"groupId":"BG000","value":"508"},{"groupId":"BG001","value":"516"},{"groupId":"BG002","value":"1024"}]}],"title":"CPS <10"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"Unknown"}],"description":"PD-L1 positivity at baseline was determined by immunohistochemistry (IHC) using both tumor and blood cells. Some efficacy outcome measures were presented using a CPS cutoff of CPS ≥10 at baseline. Participants with a CPS ≥10 were classified as PD-L1 strongly positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"216"}]}],"title":"FP Regimen"},{"categories":[{"measurements":[{"groupId":"BG000","value":"682"},{"groupId":"BG001","value":"681"},{"groupId":"BG002","value":"1363"}]}],"title":"CAPOX Regimen"}],"description":"Participants received the physicians' choice of either the FP chemotherapy regimen (cisplatin and 5FU) OR the CAPOX regimen (oxaliplatin and capecitabine). Participants were stratified by chemotherapy regimen.","paramType":"COUNT_OF_PARTICIPANTS","title":"Chemotherapy Regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"403"}]}],"title":"Western Europe/Israel/North America/Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"263"},{"groupId":"BG001","value":"262"},{"groupId":"BG002","value":"525"}]}],"title":"Asia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"326"},{"groupId":"BG001","value":"325"},{"groupId":"BG002","value":"651"}]}],"title":"Rest of World"}],"description":"Participants were stratified by geographic region using the following categories: Western Europe/Israel/North America/Australia; Asia; and Rest of World.","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"}],"populationDescription":"All randomized participants"}